Soluble apoptosis molecules in primary biliary cirrhosis: Analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C

Clinical and Experimental Immunology

Volumn 148, Issue 1, 2007, Pages 85-89

  Pelli, N ^a   Floreani, A ^b   Torre, F ^a   Delfino, A ^a   Baragiotta, A ^b   Contini, P ^a   Basso, M ^a   Picciotto, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Apoptosis; Chronic hepatitis C; Fas; PBC; TRAIL

Indexed keywords

FAS LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; URSODEOXYCHOLIC ACID;

ADULT; AGED; APOPTOSIS; ARTICLE; BILIARY CIRRHOSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; IMMUNOASSAY; LIVER HISTOLOGY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; SOLUBILITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33847638805     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03293.x     Document Type: Article

References (29)

1. Gozlan J, Nion I, Chazouilleres O et al. Soluble Fas is increased in serum of patients with primary biliary cirrhosis, but is not a useful marker for disease activity. Am J Gastroenterol 2000; 95:3328-9.
2. Harada K, Ozaki S, Gershwin ME et al. Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 1997; 26:1399-405.
3. Harada K, Kono N, Tsuneyama K et al. Cell-kinetic study of proliferating bile ductules in various hepatobiliary diseases. Liver 1998; 18:277-84.
4. Koga H, Sakisaka S, Ohishi M et al. Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997; 25:1077-84.
5. Tinmouth J, Lee M,Wanless IR et al. Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. Liver 2002; 22:228-34.
6. Faubion WA, Guicciardi ME, Miyoshi H et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999; 103:137-45.
7. Strasser A, O'Connor L. Fas ligand - caught between Scylla and Charybdis. Nat Med 1998; 4:21-2.
8. Tortorella C, Sacco R, Orlando P et al. sICAM-1, sCD95 and sCD95L levels in chronic liver diseases of different etiology. Immunopharmacol Immunotoxicol 2000; 22:19-33.
9. Zheng SJ, Wang P, Tsabary G et al. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 2004; 113:58-64.
10. Sheridan JP, Marsters SA, Pitti RM et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818-21.
11. Spierings DC, de Vries EG, Vellenga E et al. Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem 2004; 52:821-31.
12. Higuchi H, Grambihler A, Canbay A et al. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem 2004; 279:51-60.
13. Janssen HL, Higuchi H, Abdulkarim A et al. Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 2003; 39:414-20.
14. Mundt B, Kuhnel F, Zender L et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J 2003; 17:94-6.
15. Wiley SR, Schooley K, Smolak PJ et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82.
16. Hao C, Song JH, Hsi B et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 2004; 64:8502-6.
17. Lunemann JD, Waiczies S, Ehrlich S et al. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 2002; 168:4881-8.
18. Pelli N, Torre F, Delfino A et al. Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C. J Interferon Cytokine Res 2006; 26:119-23.
19. Jaeschke H, Gujral JS, Bajt ML. Apoptosis and necrosis in liver disease. Liver Int 2004; 24:85-9.
20. Fox CK, Furtwaengler A, Nepomuceno RR et al. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver 2001; 21:272-9.
21. Sedger LM, Shows DM, Blanton RA et al. IFN-gamma mediates a novel antiviral activity through dynamicmodulation of TRAIL and TRAIL receptor expression. J Immunol 1999; 163:920-6.
22. Han LH, SunWS,Ma CH et al. Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J Gastroenterol 2002; 8:1077-80.
23. Higuchi H, Bronk SF, Taniai M et al. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. J Pharmacol Exp Ther 2002; 303:461-7.
24. Rodrigues CM, Fan G,Ma X et al. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998; 101:2790-9.
25. Kountouras J, Zavos C, Chatzopoulos D. Apoptosis in hepatitis C. J Viral Hepatol 2003; 10:335-42.
26. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004; 39:273-8.
27. Sherlock S, Dooley J. Diseases of the liver and biliary system, 11th edn. Oxford: Blackwell Publishing, 2002.
28. Choi JW, Song JS, Pai SH. Associations of serum TRAIL concentrations, anthropometric variables, and serum lipid parameters in healthy adults. Ann Clin Lab Sci 2004; 34:400-4.
29. Choi JW. Associations of Fas (CD95), tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), and biochemical manifestations in elderly persons. Clin Chim Acta 2006; 365:113-8.